Abstract
Since the discovery, substantial improvement in the understanding of hepatitis B virus (HBV) virology, host immune response, and natural course, combined with the advent of effective vaccine and antiviral drugs, has led to better control for chronic HBV infection, as well elaborated and demonstrated in the chapters in this book. In particular, 183 countries have implemented vaccination program as of 2013. The estimated global population with chronic HBV infection has decreased from 350 million to 240 million in the most recent estimate in 2012. In addition, potent nucleos(t)ide analogs (NUC) with high genetic barrier to drug resistance are able to maintain long-term HBV suppression, improve liver histology, reverse hepatic fibrosis, and reduce hepatocellular carcinoma (HCC). However, there are challenges ahead to achieve eradication of HBV.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
WHO. Global immunization data. 2014. http://www.who.int/immunization/monitoring_surveillance/en/.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.
The World Bank. GNI 2013 atlas method. World development indicators database. 2014. http://www.worldbank.org/.
Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403–10.
Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat. 2015;22:409–15.
Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62:S76–86.
Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic hepatitis B virus infections. Gut. 2012;61:333–6.
Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut. 2015;64:1314–26.
Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eradicate hepatitis B virus. Nat Rev Gastroenterol Hepatol (in press).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Liaw, YF., Zoulim, F. (2016). Towards HBV Eradication: Future Perspective. In: Liaw, YF., Zoulim, F. (eds) Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-22330-8_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-22330-8_20
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-22329-2
Online ISBN: 978-3-319-22330-8
eBook Packages: MedicineMedicine (R0)